PHIA Koninklijke Philips N.V.

Philips completes sale of Domestic Appliances business to global investment firm Hillhouse Investment

Philips completes sale of Domestic Appliances business to global investment firm Hillhouse Investment



September 2, 2021

Amsterdam, the Netherlands – (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has completed the sale of the Domestic Appliances business to Hillhouse Investment, a global investment firm. The results of this transaction, which Philips on March 25, 2021, will be reported under discontinued operations in the third quarter of 2021. Philips received cash proceeds after tax and transaction-related costs of approximately EUR 3 billion.

The transaction values Domestic Appliances, a global leader with EUR 2.2 billion sales in 2020 in kitchen, coffee, garment care and home care appliances, at an enterprise value of approximately EUR 3.7 billion. The total deal value amounts to approximately EUR 4.4 billion resulting from an additional 15-year brand license agreement with annual payments that represent an estimated net present value of approximately EUR 0.7 billion.

“I am pleased that in line with our plans we have completed this transaction and concluded our major divestments,” said Frans van Houten, CEO of Royal Philips. “I am confident that the Domestic Appliances business will be able to expand on its market leadership with the support of Hillhouse Investment. In the past 12 months, Philips has further strengthened its portfolio with the launch of new products and solutions, as well as the acquisitions of Intact Vascular in image guided therapy, and BioTelemetry and Capsule Technologies in connected care. We are executing on our strategy to deliver integrated solutions that support professional healthcare customers achieve the Quadruple Aim and consumers with their health.”

“We are in a great position to continue bringing meaningful innovations to the consumer’s home in areas such as kitchen, coffee, garment care and home care appliances,” said Henk de Jong, CEO of Domestic Appliances. “We look forward to embark on this new partnership with Hillhouse Investment, building on our longstanding consumer, customer and partner relationships, as well as our market leading positions across our portfolio and the brand license partnership with Philips.”

Following the sale of Domestic Appliances, Philips’ EUR 3.2 billion Personal Health businesses will continue to shape its important role in the company’s integrated health continuum approach through products and solutions that support healthy living and prevention of diseases. Philips is a global leader in oral healthcare, personal care and mother & child care, areas that are essential building blocks of consumer health.

For further information, please contact:

Ben Zwirs

Philips Global Press Office

Tel.:

E-mail:

Derya Guzel

Philips Investor Relations

Tel.:

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

Forward-looking statements

This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Attachments



EN
02/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips expands digital pathology portfolio with cloud-enabled Philips...

Philips expands digital pathology portfolio with cloud-enabled Philips IntelliSite Pathology Solution on HealthSuite March 11, 2026 Fully cloud‑enabled solution designed to help healthcare organizations scale digital pathology adoption and workflows Amsterdam, The Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the expansion of its digital pathology portfolio with new cloud-enabled capabilities designed to help healthcare organizations scale digital diagnostics, improve productivity, and advance their transformation to fully digital workflows....

 PRESS RELEASE

Philips connects patient monitoring and diagnostics to advance platfor...

Philips connects patient monitoring and diagnostics to advance platform-based care intelligence at HIMSS26 March 10, 2026 Amsterdam, the Netherlands, and Las Vegas, USA – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today highlighted how open, interoperable, AI-enabled platforms can help health systems connect continuous patient monitoring with diagnostic insights – bringing the patient story together across time and across specialties. By connecting clinical signals with diagnostic information, Philips enables care teams to move from fragmented data to a more continuous,...

Marc Hesselink ... (+2)
  • Marc Hesselink
  • CFA

Philips/Execution is key/HOLD

Philips reported a better-than-expected 4Q25 update and a supportive CMD message. We increase our estimates, raise our target price from €23 to €26 and reiterate our Hold rating. Philips appears positioned to continue progressing operationally, but we believe consistent delivery will be required before we see meaningful outperformance versus the sector. Valuation at 15x adj EPS 2027F is in line with peers.

 PRESS RELEASE

Philips unveils Rembra CT at ECR 2026, setting a new benchmark for spe...

Philips unveils Rembra CT at ECR 2026, setting a new benchmark for speed and patient access designed to support diagnostic confidence for acute and high-demand imaging environments March 4, 2026 CE Marked and 510(k) pending, Rembra’s advanced image reconstruction technology delivers up to 106 images per second [1] and a high throughput of up to 270 patients per day [2] to support faster diagnosis by making scans available in near-real timeWith the largest-in-class 85 cm bore, Rembra accommodates challenging patient types, providing more access for complex interventions, bariatric imaging a...

 PRESS RELEASE

Philips publishes its Annual Report 2025

Philips publishes its Annual Report 2025 February 19, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course. Philips filed the Annual Report 2025 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to f...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch